✦ LIBER ✦

Chronic myelogenous leukemia and exposure to ionizing radiation — a retrospective study of 443 patients

✍ Scribed by A. Corso; M. Lazzarino; E. Morra; S. Merante; C. Astori; P. Bernasconi; M. Boni; C. Bernasconi

Publisher: Springer
Year: 1995
Tongue: English
Weight: 388 KB
Volume: 70
Category: Article
ISSN: 0939-5555
DOI: 10.1007/bf01834384

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Response of chronic myelogenous leukemia

Response of chronic myelogenous leukemia patients to COAP—splenectomy. A southwest oncology group study

✍ Jeane P. Hester; Caroline C. Waddell; Charles A. Coltman Jr; Francis S. Morrison 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB

Changes in the repair capacity of blood

Changes in the repair capacity of blood cells as a biomarker for chronic low-dose exposure to ionizing radiation

✍ Ulla G. Plappert; Bernd Stocker; Helga Fender; Theodor M. Fliedner 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

The purpose of this study was to examine whether changes in the repair capacity of blood cells could be used as a valuable biomarker for radiation exposure. To characterize the repair kinetics in nonirradiated and irradiated cells we first performed in vitro split dose experiments. DNA damage and DN

Routine clinical use of alemtuzumab in p

Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia : A nation-wide retrospective study in Austria

✍ Michael Fiegl; Andreas Falkner; Georg Hopfinger; Stefan Brugger; August Zabernig 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB 👁 1 views

## Abstract ## BACKGROUND. In previous studies, alemtuzumab demonstrated considerable activity in patients with previously treated B‐cell chronic lymphocytic leukemia (CLL), including fludarabine‐refractory disease. In this retrospective study, the authors evaluated the benefit of alemtuzumab mono

Interferon alfa-2c in chronic myelogenou

Interferon alfa-2c in chronic myelogenous leukemia (CML): Hematologic, cytogenetic and molecular-genetic response of patients with chronic phase CML previously resistant to therapy with interferon gamma

✍ Herrmann, F. ;Jonas, D. ;Helfrich, S. G. ;Lindemann, A. ;Schleiermacher, E. ;Mer 📂 Article 📅 1990 🏛 Springer-Verlag ⚖ 849 KB

Dasatinib, even at low doses, is an effe

Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients

✍ Giuseppe Visani; Massimo Breccia; Antonella Gozzini; Giorgina Specchia; Enrico M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 640 KB

Pilot study of lonafarnib, a farnesyl tr

Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy

✍ Gautam Borthakur; Hagop Kantarjian; George Daley; Moshe Talpaz; Susan O'Brien; G 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 2 views